Wednesday 26 October 2011 – Janssen Pharmaceutica, Beerse, Belgium
Program
You can download this program from the pdf in attachment at the bottom of this page.
|
8:30-9:00 |
Coffee |
|
|
9:00-9:05 |
Welcome |
Mark Martens, President of BelTox |
|
Morning session 1: Introductory lectures (chair : J. Baumeister -Ablynx & M. Cornet – UCB Pharma) |
||
|
9:05-10:05 |
Safety assessment of biologics : specific requirements for vaccines and antibodies |
R. Foster, CiToxLAB, F |
|
10:05-11:05 |
Safety assessment of biologics : regulatory perspectives
|
J.W. van der Laan, RIVM, Nl |
| 11:05-11:25 |
Coffee break |
|
|
Morning session 2: Non-clinical safety evaluation of vaccines (chair : L. Segal – GSK Biologicals) |
||
|
11:25-12:05 |
Prophylactic vaccine toxicology case study
|
S. Gould Sanofi-Pasteur, F |
|
12:05-12:45 |
Vaccine adjuvants safety evaluation
|
N. Garçon, GSK Biologicals, B |
|
12:45-13:45 |
Lunch and networking |
|
|
Afternoon session: Non-clinical safety evaluation of antibodies and nanobodies (chair : G. Bailey & I. Smyej – Johnson & Johnson) |
||
|
13:45-14:25 |
Challenges in developmental and reproductive toxicity testing of biopharmaceuticals |
G. Weinbauer, Covance, D |
| 14:25-14:55 | Choice of species for reproductive toxicity studies with biopharmaceuticals |
A. Cauvin, UCB Pharma, B |
|
14:55-15:15 |
Coffee break |
|
|
15:15-15:55 |
Immunogenicity testing in support of nonclinical studies of biotherapeutics: experiences and challenges |
M.P. Bouche, Ablynx, B |
|
15:55-16:35 |
Safety assessment of monoclonal antibodies : Specific requirements for infectious diseases
|
T.Kwaks, Crucell, Nl |
|
16:35-17:25 |
Safety assessment of Nanobodies : experienes and outlook
|
S. Jacobs, Ablynx, B |
|
17:25-17:35 |
Concluding remarks
|
M. Cornet, Beltox & chair of the Organising Committee |
|
17:35-19:00 |
Reception and networking
|
|
|
Organising Committee : Judith Baumeister (Ablynx), Annick Cauvin (UCB Pharma),
Miranda Cornet (UCB Pharma), Ilham Smyej (Johnson & Johnson), Lawrence Segal (GSK Biologicals) with the technical assistance of Marleen Hallam (BelTox) and Karin Van Tulden (Johnson & Johnson) |
||